LONZA N 2. LINIELL

LONZA N 2. LINIE

577.8CHFD
+7.8+1.37%
Last update at Mar 3, 22:51 GMT
CHF
No tradesPre-market
See on Supercharts

LONNE fundamentals

Key facts

Market capitalization‪40.62 B‬CHF
Founded1897
Employees (FY)‪18.69 K‬
CEOWolfgang Wienand
Websitelonza.com
About

Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.

Ownership
‪‪70.32 M‬‬
Free Float shares
‪‪68.19 M‬‬ (96.96%)
Closely held shares
‪‪2.14 M‬‬ (3.04%)
Free Float shares
‪‪68.19 M‬‬ (96.96%)
Closely held shares
‪‪2.14 M‬‬ (3.04%)
Capital structure
Market cap
‪‪40.62 B‬‬
Debt
‪‪4.71 B‬‬
Minority interest
‪‪60.00 M‬‬
Cash & equivalents
‪‪1.71 B‬‬
Enterprise value
‪‪43.68 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪40.62 B‬‬
Price to earning ratio (P/E)
63.90x
Price to sales ratio (P/S)
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
63.90x
Price to sales ratio (P/S)
Valuation ratios
‪0.00‬
‪1.60‬
‪3.20‬
‪4.80‬
‪6.40‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪16.00‬
‪32.00‬
‪48.00‬
‪64.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪6.5%‬
‪10.5%‬
‪14.5%‬
‪18.5%‬
‪22.5%‬
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪0.00‬
‪‪1.00 B‬‬
‪‪2.00 B‬‬
‪‪3.00 B‬‬
‪‪4.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪900.00 M‬‬
‪‪1.80 B‬‬
‪‪2.70 B‬‬
‪‪3.60 B‬‬

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
2021
2022
2023
2024
2025
‪0.00‬
‪‪2.00 B‬‬
‪‪4.00 B‬‬
‪‪6.00 B‬‬
‪‪8.00 B‬‬
Actual
Estimate
Earnings
Next:Jan 28, 2026
2021
2022
2023
2024
2025
‪0.00‬
‪4.50‬
‪9.00‬
‪13.50‬
‪18.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

LONNE does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
H2 '22
H1 '23
H2 '23
H1 '24
H2 '24
‪‪−1.60 B‬‬
‪0.00‬
‪‪1.60 B‬‬
‪‪3.20 B‬‬
‪‪4.80 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪4.00 B‬‬
‪‪8.00 B‬‬
‪‪12.00 B‬‬
‪‪16.00 B‬‬
Assets
Liabilities